Top Indian drugmakers bank on bilateral talks for relief from planned US tariffs (February 20)
Indian drugmakers are hoping that bilateral discussions between the country and the United States will help them steer clear of President Donald Trump's plan to levy at least 25% tariffs on pharmaceutical imports,
India, Modi and Trump
Indian pharmaceutical companies will be able to retain their dominant market share in the U.S. in selling generic drugs even ...
India should propose a 'zero-for-zero' tariff strategy to the US for addressing America's proposed reciprocal tariff hikes, ...
GTRI founder Ajay Srivastava explains that the threat of reciprocal tariffs is not cause of concern because 75 per cent of US ...
India's benchmark indexes fell for the fourth straight session and recorded weekly losses, weighed down by auto and pharma ...
US President Trump has imposed a 25 per cent tariff on semiconductor imports, raising costs for US tech firms and disrupting ...
Commerce Department to hold sectoral consultations with other Ministries to sensitise them on India-US trade, tariff issues ...
IPA primarily represents companies specializing in producing generic drugs, which are lower-cost versions of branded ...
The Indian rupee's direction this week will be shaped by the dollar's reaction to its recent correction and whether worries ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback